EBR Systems (ASX: EBR) has taken another significant step towards expanding the commercial reach of its wireless heart pacing technology, with US Medicare authorities proposing national coverage for its WiSE System. The development could remove a major barrier to hospital adoption, improve patient access and accelerate commercial growth across the United States.
With regulatory approval already secured and its commercial infrastructure expanding, EBR is approaching an important turning point. The next question is how quickly broader reimbursement could translate into higher procedure volumes and stronger revenue.
Key Numbers
- 157 implants: Total commercial WiSE procedures completed by 30 September 2026, including 40 during the September quarter.
- US$7.49 million: Revenue for the nine months ended 30 September 2026, compared with US$682,000 a year earlier.
- US$95.8 million: Cash, restricted cash and marketable securities at 30 September 2026.
- 100 physicians: Trained to perform WiSE procedures across 40 activated hospitals.
- 16 February 2027: Expected date for the final US Medicare national coverage determination.
Medicare Proposal Could Unlock Broader US Adoption
On 20 November 2026, EBR confirmed that the US Centers for Medicare & Medicaid Services (CMS) had proposed a National Coverage Determination for its WiSE Cardiac Resynchronisation Therapy System.
Published on 18 November, the proposal would establish national Medicare coverage under the Coverage with Evidence Development pathway.
Importantly, the proposed coverage would extend across traditional Medicare and Medicare Advantage, potentially removing reimbursement uncertainty affecting approximately half the Medicare population.
For hospitals, clearer reimbursement arrangements could simplify treatment decisions and encourage greater adoption of WiSE technology.
The proposal would require eligible patients to participate in an approved clinical evidence programme, including the proposed WiSE-CHOICE study, which would assess survival and heart failure hospitalisations over at least 24 months.
While the determination remains subject to consultation, it represents meaningful progress towards expanding access to EBR's technology.
What Stands Out to Us
EBR's competitive advantage lies in its proprietary wireless pacing technology, which received US Food and Drug Administration approval in April 2025.
Unlike conventional cardiac resynchronisation systems that rely on leads to stimulate the heart's left ventricle, WiSE provides an alternative for patients who cannot receive traditional treatment.
This differentiation gives EBR a specialised position within the cardiac device market, supported by regulatory approvals, intellectual property and growing clinical experience.
Commercial foundations are also taking shape.
By September 2026, EBR had secured 57 purchasing contracts, trained 100 physicians and activated 40 hospitals.
Although September-quarter implant volumes were below the preceding quarter, the expanding hospital network provides opportunities to increase utilisation without relying entirely on new account openings.
Revenue growth is encouraging, with nine-month revenue reaching US$7.49 million.
However, profitability remains a longer-term objective. Operating cash outflows totalled US$54.7 million over the same period, while debt obligations of US$41.8 million fall due within 12 months of 30 September 2026.
The company's substantial liquidity position provides financial flexibility, although refinancing and cash management remain important priorities.
What EBR Systems Is Doing Now
EBR is strengthening its US commercial operations, including recruiting a new Chief Commercial Officer and focusing on improving procedure volumes across its existing hospital network.
The company has also launched its WiSE Coupler accessory and achieved ISO 13485 certification at its expanded Santa Clara manufacturing facility.
Once fully operational and subject to remaining requirements, the facility is designed to support annual production of up to 9,600 systems.
Meanwhile, increased Medicare inpatient reimbursement rates took effect on 1 October 2026, potentially improving hospital economics for eligible procedures.
Together, these initiatives are building the commercial and manufacturing foundations needed to support greater adoption.
Insight: Could Medicare Coverage Accelerate EBR's Commercial Breakthrough?
We believe the proposed Medicare coverage represents one of EBR's most commercially significant developments since receiving FDA approval. By addressing reimbursement uncertainty, the company could unlock greater demand across an established network of hospitals and trained physicians. Its differentiated technology and growing commercial infrastructure provide a credible foundation for expansion. While cash consumption, manufacturing margins and debt refinancing require careful management, increasing procedure volumes could progressively improve operating efficiency. The strongest evidence of commercial success will be sustained implant growth accompanied by improving margins and a clearer path towards positive cash flow.
What Happens Next?
Public consultation on the proposed Medicare determination closes on 18 December 2026, with a final decision expected by 16 February 2027.
A favourable outcome could provide an important catalyst for broader US adoption, although coverage would remain subject to clinical evidence requirements.
The next indicators will be hospital utilisation, quarterly implant volumes, revenue growth and manufacturing margins.
For EBR, the combination of an FDA-approved technology, expanding hospital relationships and potentially broader Medicare coverage creates an increasingly compelling commercial opportunity. Converting those advantages into sustainable growth will be the company's defining challenge over the next phase of its development.